Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22/CD19 CAR-T Cell Immunotherapy for Consolidation Therapy in Relapsed/Refractory Aggressive B-cell Lymphoma
NCT07779018Phase 2Recruiting
- Sponsor
- Liping Dou
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of cd22 car-t + cd19 car-t in diffuse large B-cell lymphoma (DLBCL), sponsored by Liping Dou. Started Apr 2026; status: recruiting.
02
Drugs
cd22 car-t + cd19 car-t
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07779018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779018.